This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Orexigen Therapeutics: FDA Panel Live Blog

WASHINGTON. D.C. ( TheStreet) -- Orexigen Therapeutics (OREX - Get Report) brings its weight-loss drug Contrave in front of an advisory committee of the U.S. Food and Drug Administration today.

Orexigen will try to do what competitors Arena Pharmaceuticals (ARNA - Get Report) and Vivus (VVUS - Get Report) failed to do earlier this year -- convince a group of outside experts that the company has a weight-loss drug that is both effective and safe for the millions of obese Americans who can't seem to shed the pounds with diet and exercise alone.

Last Friday, an FDA review concluded that Contrave helped patients lose weight but regulators also raised concerns about the drug's safety, most notably a small increase in heart rate and blood pressure.

The FDA advisory panel will be asked to assess Contrave's efficacy and safety and vote on whether to recommend the drug's approval. An approval decision by FDA is expected on Jan. 31, 2011.

The Contrave advisory panel comes not only after FDA rejected competing weight-loss drugs from Vivus and Arena, but also a few days after a different FDA panel voted to recommend the expanded surgical use of Allergan's (AGN - Get Report) stomach-shrinking lap band.

Orexigen shares will be halted all day Tuesday during the FDA advisory panel for Contrave. The stock closed Monday at $4.76.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AGN $306.70 0.00%
ARNA $4.52 0.00%
OREX $4.77 0.00%
VVUS $2.31 0.00%
AAPL $126.00 0.00%

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs